Receptor tyrosine kinase inhibitors in cancer

Nasim Ebrahimi; Elmira Fardi; Hajarossadat Ghaderi; Sahar Palizdar; Roya Khorram; Reza Vafadar; Masoud Ghanaatian; Fatemeh Rezaei-Tazangi; Payam Baziyar; Amirhossein Ahmadi; Michael R. Hamblin; Amir Reza Aref

doi:10.1007/s00018-023-04729-4

Receptor tyrosine kinase inhibitors in cancer

Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Masoud Ghanaatian, Fatemeh Rezaei-Tazangi, Payam Baziyar, Amirhossein Ahmadi, Michael R. Hamblin, Amir Reza Aref

Laser Research Centre

Research output: Contribution to journal › Review article › peer-review

27 Citations (Scopus)

Abstract

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

Original language	English
Article number	104
Journal	Cellular and Molecular Life Sciences
Volume	80
Issue number	4
DOIs	https://doi.org/10.1007/s00018-023-04729-4
Publication status	Published - Apr 2023

Keywords

Cancer therapy
Drug resistance
Immune therapy
RTK inhibitors
Targeted therapy

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Pharmacology
Cellular and Molecular Neuroscience
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00018-023-04729-4

Cite this

@article{a7388fed964649b29a0f44352668b3d0,

title = "Receptor tyrosine kinase inhibitors in cancer",

abstract = "Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.",

keywords = "Cancer therapy, Drug resistance, Immune therapy, RTK inhibitors, Targeted therapy",

author = "Nasim Ebrahimi and Elmira Fardi and Hajarossadat Ghaderi and Sahar Palizdar and Roya Khorram and Reza Vafadar and Masoud Ghanaatian and Fatemeh Rezaei-Tazangi and Payam Baziyar and Amirhossein Ahmadi and Hamblin, {Michael R.} and Aref, {Amir Reza}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.",

year = "2023",

month = apr,

doi = "10.1007/s00018-023-04729-4",

language = "English",

volume = "80",

journal = "Cellular and Molecular Life Sciences",

issn = "1420-682X",

publisher = "Birkhauser Verlag Basel",

number = "4",

}

TY - JOUR

T1 - Receptor tyrosine kinase inhibitors in cancer

AU - Ebrahimi, Nasim

AU - Fardi, Elmira

AU - Ghaderi, Hajarossadat

AU - Palizdar, Sahar

AU - Khorram, Roya

AU - Vafadar, Reza

AU - Ghanaatian, Masoud

AU - Rezaei-Tazangi, Fatemeh

AU - Baziyar, Payam

AU - Ahmadi, Amirhossein

AU - Hamblin, Michael R.

AU - Aref, Amir Reza

PY - 2023/4

Y1 - 2023/4

N2 - Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

AB - Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

KW - Cancer therapy

KW - Drug resistance

KW - Immune therapy

KW - RTK inhibitors

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85150849869&partnerID=8YFLogxK

U2 - 10.1007/s00018-023-04729-4

DO - 10.1007/s00018-023-04729-4

M3 - Review article

C2 - 36947256

AN - SCOPUS:85150849869

SN - 1420-682X

VL - 80

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

IS - 4

M1 - 104

ER -

Receptor tyrosine kinase inhibitors in cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this